LONDON, July 9 (Reuters) - GlaxoSmithKline Plc has won a licence extension in Europe for Seretide, allowing its top-selling inhaler product to be used in a wider population of patients with the lung ...

Please provide your email address to receive an email when new articles are posted on . A Montreal Cognitive Assessment score of 16 or less, which implies dementia, predicted errors in using inhalers.